



## ADITEC MEETING 2019

### Advanced Immunization Technologies 30<sup>th</sup> September - 2<sup>nd</sup> October 2019

Aula Magna Rettorato, University of Siena,  
Via Banchi di Sotto 55, Siena, Italy

### Agenda

#### 30<sup>th</sup> September 2019 – Day 1

13:30 – 14:45	Registration and Buffet lunch	
15:00 – 15:40	Opening Session	
15:00	Welcome Address	<p><b>Francesco Frati</b> Rector of the University of Siena</p> <p><b>Monica Barni</b> Vice-President of the Tuscany Region</p> <p><b>Luisa Bracci</b> Director Department of Medical Biotechnology</p> <p><b>Donata Medaglini</b> University of Siena, SVA</p> <p><b>Rino Rappuoli</b> Glaxo Smith Kline</p>
15:25	New Challenges for Vaccines	
15:45 - 18:45	<b>Vaccine Adjuvants &amp; Delivery Systems</b>	
	<b>Chair: Steven Reed</b> , IDRI - Infectious Disease Research Institute	
15:45	Innovations in Vaccine Delivery, Adjuvant Development and Global Access	<b>Steven Reed</b> IDRI
16:05	Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine	<b>Emilio Siena</b> Glaxo Smith Kline
16:25	Depot or not –investigating the role for vaccine depots in immune induction	<b>Dennis Christensen</b> Statens Serum Institut
16:45	Self-amplifying RNA vaccines	<b>John S. Tregoning</b> Imperial College London
17:05	GMMA-based vaccine against <i>Salmonella enterica</i> serovar <i>Typhimurium</i> induces long term immune response and protection from challenge	<b>Fabio Fiorino</b> University of Siena
17:25	Active and passive immunization utilizing non-viral delivery of replicating viral RNA as a gene-expression platform	<b>Jesse H. Erasmus</b> IDRI
17:45	Potent cytomegalovirus-specific CD8 T-cell and neutralizing antibody induction without vector-neutralizing antibody inhibition: first-in-man study of replication-deficient lymphocytic choriomeningitis virus vectors	<b>Daniel D. Pinschewer</b> Hookipa Pharma, University of Basel
18:05	Enhanced immunogenicity of mitochondrial localised proteins in cancer cells	<b>Gennaro Prota</b> University of Oxford
18:25	General Discussion	
18:45	<b>Welcome Cocktail – Cortile Palazzo del Rettorato, University of Siena</b>	

# 1<sup>st</sup> October 2019 – Day 2

## 09:00 – 11:00 Vaccines at Extremes of Ages

**Chairs:** **Claire-Anne Siegrist**, University of Geneva – **Claudio Franceschi**, University of Bologna

09:00	Protecting the very young through maternal immunization: an immunology update	<b>Claire-Anne Siegrist</b> University of Geneva
09:20	Inflammaging, immunobiography and vaccination	<b>Claudio Franceschi</b> University of Bologna
09:40	The strategies of immunological memory in the elderly	<b>Eva Piano Mortari</b> Bambino Gesù Children's Hospital
10:00	The length of the Vi-polysaccharide chain in a Vi-CRM197 conjugate vaccine has a significant effect on the induction of a short-lived versus persistent immune response	<b>Stefania P. Bjarnarson</b> National University Hospital of Iceland - University of Iceland
10:20	The induction of fully functional T follicular helper cells is a key requirement for neonatal B cell responses elicited with a single immunization using the CAF01 adjuvant	<b>Maria Vono</b> University of Geneva

10:40 – 11:00 General Discussion

## 11:00– 11:30 Coffee Break

## 11:30 – 13:00 Global Efforts to Support Vaccine R&D

**Chair:** **Rino Rappuoli**, Glaxo Smith Kline

11:30	IMI2 vaccine related portfolio	<b>Pierre Meulien</b> IMI II Executive Director
11:45	The EDCTP Programme	<b>Ole F. Olesen</b> Director Int Cooperation EDCTP
12:00	The Human Vaccines Project 2.0 Scientific Strategic Plan: Towards Studies at Scale to Figure Out the Rules of Engagement of the Human Immune System	<b>Jaap Goudsmit</b> Harvard School of Public Health
12:15	An industry perspective on the need for new vaccines Research & Innovation strategies	<b>Philippe Denoel</b> Vaccines Europe

12:30 – 13:00 General Discussion

## 13:00 – 14:00 Lunch

## 14:00 – 15:00 Poster session

## 15:00– 16:40 Biomarkers of Human Immune-response to Vaccination and of Vaccine Safety

**Chair:** **Tom H. M. Ottenhoff**, Leiden University Medical Center

15:00	Introduction	<b>Tom H. M. Ottenhoff</b> Leiden University Medical Center
15:20	Preventative and therapeutic vaccines to HIV or SIV require effective innate immune responses and CD4+ memory stem cells	<b>Yufei Wang</b> King's College London
15:40	Exploring new markers of innate responses to the rVSV-ZEBOV EBOLA vaccine	<b>Paola Martinez-Murillo</b> University of Geneva
16:00	Characterization of pre-existing antibodies and its impact on the avidity of antibody induced by rVSV-ZEBOV vaccine in African cohorts	<b>Shravya Sowdamini Nakka</b> University of Gothenburg

16:20 – 16:40 General Discussion

## 16:40 – 18:00 ADITEC Steering Committee

**18:45 Guided Tour Collection of Art Works, Palazzo Sansedoni**

**19:30 Social Dinner - Palazzo Sansedoni, Fondazione Monte dei Paschi di Siena**

## 2<sup>nd</sup> October 2019 – Day 3

<b>08:45 – 10:25</b>	<b>System Biology and Computational Models for the Analysis of Vaccine Responses</b> <b>Chairs: Yvan Saeys</b> , University of Ghent - <b>Simone Furini</b> , University of Siena	
8:45	Introduction	<b>Yvan Saeys</b> University of Ghent
9:05	Systematic characterization of human response to H1N1 influenza vaccination through the construction and integration of personalized transcriptome response profiles	<b>Carlo De Intinis</b> Glaxo Smith Kline - University of Turin
9:25	Transcriptomic signatures induced by VSV-ZEBOV vaccination in adult cohorts in Europe, Africa and North-America	<b>Tom H.M. Ottenhoff</b> <b>Eleonora Vianello</b> Leiden University Medical Center
9:45	Computational analysis of multiparametric flow cytometric data to dissect the B cell response upon immunization with a <i>Mycobacterium tuberculosis</i> chimeric antigen	<b>Annalisa Ciabattini</b> University of Siena
10:05 -10:25	General Discussion	
<b>10:25 – 11:00</b>	<b>Coffee Break</b>	
<b>11:00 – 12:30</b>	<b>Synergies with other EU Vaccine Projects</b> <b>Chair: Donata Medaglini</b> , University of Siena	
11:00	Introduction	<b>Donata Medaglini</b> University of Siena
11:10	Development of a vaccine based on GMMA against invasive non-typhoidal Salmonella disease: towards Phase 1 testing in humans, Vacc-iNTS synergies with ADITEC	<b>Laura B. Martin</b> GVGH
11:20	A novel approach to isolate human monoclonal antibodies against antimicrobial-resistant <i>Neisseria gonorrhoeae</i>	<b>Emanuele Andreano</b> Toscana Life Science
11:30	TRANSVAC2 - Transforming the European vaccine landscape	<b>Catarina Luis</b> EVI
11:40	Vaccine Safety and Immunogenicity Signatures of Adult and Pediatric Responses to the rVSV-ZEBOV Ebola Vaccine (VSV-EBOVAC and VSV-EBOPLUS)	<b>Claire-Anne Siegrist</b> University of Geneva
11:50	Tuberculosis Vaccine Initiative (TBVAC2020)	<b>Tom H.M. Ottenhoff</b> Leiden University Medical Center
12:00	Standardization and development of assays for assessment of influenza vaccine correlates of protection (FLUCOP)	<b>Patricia Londono-Hayes</b> Sanofi Pasteur <b>Emanuele Montomoli</b> University of Siena
12:10 – 12:30	General discussion	
<b>12:30 – 12:45</b>	<b>Concluding Remarks</b>	<b>Rino Rappuoli</b> Glaxo Smith Kline <b>Donata Medaglini</b> University of Siena
<b>12:45 – 14:00</b>	<b>Lunch</b>	

**Gold Sponsor**

BILL & MELINDA  
GATES *foundation*



**Silver Sponsor**



**Bronze Sponsor**



The ADITEC project has received funding from the European Union's Seventh Program for Research, Technological Development and Demonstration under grant agreement No. 280873.